, with chemotherapy for stage III or IV Hodgkin's lymphoma, N Engl J Med, vol.378, pp.331-344, 2018.

O. A. O'connor, J. K. Lue, A. Sawas, J. E. Amengual, C. Deng et al.,

, Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial, Lancet Oncol, vol.19, issue.2, pp.257-266, 2018.

S. Viviani, P. L. Zinzani, A. Rambaldi, E. Brusamolino, A. Levis et al.,

, Michelangelo Foundation

, Gruppo Italiano di Terapie Innovative nei Linfomi

L. Intergruppo-italiano, ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned, N Engl J Med, vol.365, issue.3, pp.203-215, 2011.

J. W. Friedberg, A. Forero-torres, R. E. Bordoni, and V. Cline,

P. J. Flynn, Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged ?60 years with HL, vol.130, pp.2829-2837, 2017.

A. Younes, A. Santoro, and M. Shipp, Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial, Lancet Oncol, vol.17, issue.9, pp.1283-1294, 2016.

R. Chen, P. L. Zinzani, and M. A. Fanale, Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma, J Clin Oncol, vol.35, pp.2125-2132, 2017.

, Annexe 1 : Classification des tumeurs du tissu lymphoïde selon l'OMS (édition révisée

, Annexe 2 : Classification d'Ann Arbor Annexe 4 : Classification de Lugano (CR, complete response ; PR

, Critères pronostiques de l'EORTC, vol.5

, Critères pronostiques du GHSG, vol.6

, Annexe 7 : score IPS (stades avancés)